GlaxoSmithKline Divests Brands in Australia for $271 Million - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GlaxoSmithKline Divests Brands in Australia for $271 Million


ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline (GSK) is selling the majority of its ‘classic brands’ in Australia to Aspen Global for approximately £172 million ($271.1 million) in cash. The move is part of GSK’s ongoing strategy to simplify business by selling low-growth and noncore assets in order to focus on priority brands, products and pipeline opportunities.

The divested brands comprise 25 products that have been genericised or that are no longer promoted by the company, including the herpes medicine Valtrex, beta-lactam antibiotic Timentin, and the epilepsy and bipolar drug Lamictal. The brands generated around £83 million ($130.8 million) in total sales in 2011 and £31 million ($48.9 million) in the first half of 2012. In a statement, GSK explained that revenues for the products had gradually declined in recent years because of “local market price reductions and generic competition”.

However, Aspen added in a statement, “Whilst the Products received little promotional focus from GSK, Aspen is confident that it will be able to leverage its proven ability to reinvigorate older brands and the Products’ considerable brand equity in order to enhance the value of the portfolio.”

The divestment is expected to be completed in the fourth quarter of this year, subject to regulatory approvals.

Earlier this year, GSK divested several over-the-counter brands in select territories to Aspen for approximately $264.7 million.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here